Reprogrammed viruses as cancer therapeutics

Targeted, armed and shielded

Roberto Cattaneo, Tanner Miest, Elena V. Shashkova, Michael A Barry

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

Original languageEnglish (US)
Pages (from-to)529-540
Number of pages12
JournalNature Reviews Microbiology
Volume6
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Viruses
Neoplasms
Capsid
Prodrugs
Combination Drug Therapy
Polymers
Therapeutics
Radiation
Cytokines
Safety
Renaissance

ASJC Scopus subject areas

  • Microbiology

Cite this

Reprogrammed viruses as cancer therapeutics : Targeted, armed and shielded. / Cattaneo, Roberto; Miest, Tanner; Shashkova, Elena V.; Barry, Michael A.

In: Nature Reviews Microbiology, Vol. 6, No. 7, 07.2008, p. 529-540.

Research output: Contribution to journalArticle

@article{4f828e2d96e24fcfbf845c857f5361d7,
title = "Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded",
abstract = "Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.",
author = "Roberto Cattaneo and Tanner Miest and Shashkova, {Elena V.} and Barry, {Michael A}",
year = "2008",
month = "7",
doi = "10.1038/nrmicro1927",
language = "English (US)",
volume = "6",
pages = "529--540",
journal = "Nature Reviews Microbiology",
issn = "1740-1526",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Reprogrammed viruses as cancer therapeutics

T2 - Targeted, armed and shielded

AU - Cattaneo, Roberto

AU - Miest, Tanner

AU - Shashkova, Elena V.

AU - Barry, Michael A

PY - 2008/7

Y1 - 2008/7

N2 - Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

AB - Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

UR - http://www.scopus.com/inward/record.url?scp=45449114994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449114994&partnerID=8YFLogxK

U2 - 10.1038/nrmicro1927

DO - 10.1038/nrmicro1927

M3 - Article

VL - 6

SP - 529

EP - 540

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

SN - 1740-1526

IS - 7

ER -